Given they have $10M in CR funds and now up to $8M in CLIA waiver support, part of the $10M could be used for ramping manufacturing of the units with additional staff / equipment etc.
$3M of the CR was to support this. With a further $8M available, you would think that there should be enough funds to support that growth. Further, if the CLIA trial costs less than the $8M from my understanding, LDX can still retain those funds for use elsewhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)